# Oxford Cannabinoid Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxford-cannabinoid-technologies

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.oxcantech.com
- Total disclosed funding: $10M
- Latest round: Series A (Jun 28, 2018)
- Investors on record: 1

## About

Oxford Cannabinoid Technologies Ltd. focuses on developing innovative pharmaceuticals targeting the Endocannabinoid System, aiming to provide non-addictive alternatives for managing chronic pain and oncology-related symptoms.Founded in 2017 in Oxford, UK, Oxford Cannabinoid Technologies Ltd. specializes in pharmaceuticals targeting the Endocannabinoid System. The company raised GBP 7.6 million in Series A financing on June 28, 2018, led by Casa Verde Capital. The firm has successfully completed two funding deals to date. Tarek Tabsh is recognized as the founder of the company, while Clarissa Sowemimo-Coker serves as the CEO.Oxford Cannabinoid Technologies Ltd. specializes in developing innovative pharmaceuticals that target the Endocannabinoid System (ECS). Their core offerings include proprietary derivatives and novel chemical entities aimed at alleviating chronic pain and oncology-related symptoms. These products are in various clinical trial stages, focusing on providing non-addictive alternatives to traditional pain medications, thereby reducing the reliance on opioids. Their clientele comprises healthcare providers and institutions in the United States and European markets, including hospitals, clinics, and research facilities seeking advanced therapeutic options for patients.In the most recent year, 2023, Oxford Cannabinoid Technologies Ltd. reported a revenue of GBP 0, with an EBITDA of GBP -18,280. The company’s revenue structure primarily derives from partnerships with healthcare providers and institutions utilizing its pharmaceutical products in treatment regimens, often through direct sales to healthcare facilities.Oxford Cannabinoid Technologies Ltd. is strategically planning to expand its product line with new ECS-targeted therapies designed to launch in the coming years. The company aims to enter additional markets across Europe and the United States by late 2024. The GBP 7.6 million raised in Series A financing will be utilized to support research and development for these new products and to facilitate market entry strategies.

## Funding rounds

- Series A, Jun 28, 2018, $10M — Casa Verde Capital

## Investors

- Casa Verde Capital (https://capitalatlas.ai/funds/casa-verde-capital) — Series A